Baicalin, a flavonoid compound extracted from Scutellaria baicalensis Georgi, has been shown to possess various pharmacological activities, including anti-tumor effects. In this review, we summarize the current studies on the anti-tumor effects of baicalin.
Firstly, baicalin has been reported to inhibit the proliferation and induce apoptosis of various tumor cells, including breast cancer, colon cancer, lung cancer, liver cancer, and prostate cancer cells. Baicalin-induced apoptosis is mediated through several pathways, including the mitochondrial pathway, death receptor pathway, and endoplasmic reticulum stress pathway.
Secondly, baicalin has been demonstrated to possess anti-angiogenic activity by inhibiting the expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR), as well as reducing the formation of new blood vessels. Moreover, baicalin has been shown to enhance the efficacy of chemotherapy and radiotherapy by sensitizing tumor cells to these treatments.
Lastly, baicalin has been found to modulate the immune response by increasing the activity of natural killer cells and macrophages, as well as promoting the differentiation of T cells into T helper 1 (Th1) cells.
In conclusion, baicalin possesses promising anti-tumor effects and has the potential to be developed into a novel anti-cancer agent. However, further preclinical and clinical studies are still needed to elucidate its mechanism of action and to evaluate its safety and efficacy.
Baicalin, a flavonoid compound extracted from Scutellaria baicalensis Georgi, has been shown to possess various pharmacological activities, including anti-tumor effects. In this review, we summarize the current studies on the anti-tumor effects of baicalin.
Firstly, baicalin has been reported to inhibit the proliferation and induce apoptosis of various tumor cells, including breast cancer, colon cancer, lung cancer, liver cancer, and prostate cancer cells. Baicalin-induced apoptosis is mediated through several pathways, including the mitochondrial pathway, death receptor pathway, and endoplasmic reticulum stress pathway.
Secondly, baicalin has been demonstrated to possess anti-angiogenic activity by inhibiting the expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR), as well as reducing the formation of new blood vessels. Moreover, baicalin has been shown to enhance the efficacy of chemotherapy and radiotherapy by sensitizing tumor cells to these treatments.
Lastly, baicalin has been found to modulate the immune response by increasing the activity of natural killer cells and macrophages, as well as promoting the differentiation of T cells into T helper 1 (Th1) cells.
In conclusion, baicalin possesses promising anti-tumor effects and has the potential to be developed into a novel anti-cancer agent. However, further preclinical and clinical studies are still needed to elucidate its mechanism of action and to evaluate its safety and efficacy.